Robert W. Baird Reiterates “Hold” Rating for LHC Group (LHCG)

LHC Group (NASDAQ:LHCG)‘s stock had its “hold” rating restated by equities researchers at Robert W. Baird in a note issued to investors on Tuesday. They presently have a $63.00 price target on the health services provider’s stock. Robert W. Baird’s price target suggests a potential downside of 3.30% from the company’s previous close.

Several other analysts have also commented on LHCG. Jefferies Group LLC raised their price target on shares of LHC Group from $56.00 to $65.00 and gave the company a “buy” rating in a research report on Monday, May 15th. Zacks Investment Research lowered shares of LHC Group from a “buy” rating to a “hold” rating in a research report on Thursday, July 6th. Royal Bank Of Canada reiterated a “buy” rating and issued a $69.00 target price on shares of LHC Group in a research report on Monday, May 15th. BidaskClub lowered shares of LHC Group from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 12th. Finally, Benchmark Co. lifted their target price on shares of LHC Group from $63.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, June 8th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $66.60.

Shares of LHC Group (NASDAQ LHCG) traded down 0.18% during midday trading on Tuesday, hitting $65.15. 165,602 shares of the stock were exchanged. The firm’s 50-day moving average is $63.01 and its 200-day moving average is $59.34. LHC Group has a 12 month low of $32.04 and a 12 month high of $69.35. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of 28.83 and a beta of 0.76.

LHC Group (NASDAQ:LHCG) last released its quarterly earnings data on Wednesday, August 2nd. The health services provider reported $0.63 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.54 by $0.09. The firm had revenue of $260.20 million for the quarter, compared to analyst estimates of $254.10 million. LHC Group had a net margin of 4.13% and a return on equity of 9.62%. The business’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.52 earnings per share. Equities research analysts predict that LHC Group will post $2.39 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Robert W. Baird Reiterates “Hold” Rating for LHC Group (LHCG)” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://transcriptdaily.com/2017/09/13/robert-w-baird-reiterates-hold-rating-for-lhc-group-lhcg.html.

In other LHC Group news, COO Donald Dwayne Stelly sold 2,650 shares of LHC Group stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $65.34, for a total transaction of $173,151.00. Following the completion of the sale, the chief operating officer now directly owns 109,235 shares in the company, valued at $7,137,414.90. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Coliseum Capital Management, L sold 14,450 shares of LHC Group stock in a transaction dated Friday, June 16th. The shares were sold at an average price of $65.69, for a total transaction of $949,220.50. The disclosure for this sale can be found here. 14.80% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the stock. Federated Investors Inc. PA grew its holdings in shares of LHC Group by 4.2% in the second quarter. Federated Investors Inc. PA now owns 1,622 shares of the health services provider’s stock valued at $110,000 after purchasing an additional 66 shares in the last quarter. Acrospire Investment Management LLC grew its holdings in shares of LHC Group by 30.8% in the second quarter. Acrospire Investment Management LLC now owns 1,700 shares of the health services provider’s stock valued at $115,000 after purchasing an additional 400 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of LHC Group by 758.0% in the second quarter. Cubist Systematic Strategies LLC now owns 1,716 shares of the health services provider’s stock valued at $116,000 after purchasing an additional 1,516 shares in the last quarter. Invictus RG acquired a new position in shares of LHC Group in the first quarter valued at approximately $125,000. Finally, US Bancorp DE grew its holdings in shares of LHC Group by 25.1% in the first quarter. US Bancorp DE now owns 2,683 shares of the health services provider’s stock valued at $145,000 after purchasing an additional 539 shares in the last quarter. Hedge funds and other institutional investors own 85.93% of the company’s stock.

About LHC Group

LHC Group, Inc is a holding company. The Company provides post-acute healthcare services to patients through its home nursing agencies, hospice agencies, community-based services agencies and long-term acute care hospitals (LTACHs). The Company operates through four segments: home health services, hospice services, community-based services and facility-based services.

Analyst Recommendations for LHC Group (NASDAQ:LHCG)

Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply